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Table 1
Patient Characteristics HDT-ASCR n¼20 alloSCT n¼20
Median age in years (range) 51 (33-70) 55 (34-69)
Median number of previous
lines of therapy (range)
2 (2-4) 3 (2-7)
Chemosensitive 19/20 (95%) 20/20 (100%)
CR 8 7
PR 11 13
Median remission duration
(months) prior to
re-induction therapy
11.5 (0*-31) 5 (0*-12)
Remission duration  12 months
from re-induction therapy
11/20 (55%) 20/20 (100%)
* Denotes chemorefractory disease prior to re-induction.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166 S155recorded an ANC <0.5x109/L or a platelet count <10x109/L
respectively, during the ﬁrst 30 days post HCT. Durable
chimerism was achieved in 45 (96%) patients. The cumula-
tive incidence of grade II-IV acute GVHD at day 100 was 12%
and extensive chronic GVHD at 1-yr was 36%. Non-relapse
mortality (NRM) at 3 years was 7%. The median follow up for
all patients was 1142 days and 1525 days (range; 365-3667)
for the 34 (72%) living patients. The 36-month probability of
progression free and overall survival (OS) was 40% and 79%
respectively. It is noteworthy that among the 23 patients
with progressive disease after TLI-ATG, 11 were returned to
durable (>1 year) complete remission without subsequent
relapse following a donor lymphocyte infusion or chemo-
radiotherapy. 13 patients died (relapse¼8 and other
causes¼5). Proportional hazards model showed improved
relapse free survival with higher CD3+ donor chimerism
(p¼0.01). We conclude that for patients with lymphoma
relapse after auto-HCT, allogeneic HCT from a sibling or
unrelated donor using TLI-ATG conditioning was a well
tolerated outpatient procedure, did not induce signiﬁcant
cytopenias and was associated with 3 year NRM of<10%. It is
unlikely that TLI-ATG conditioning itself provided long-term
lymphoma control in these heavily pre-treated patients, with
advanced disease. Rather the 79% 3-yr OS and the fact that
the majority of patients continue in durable CR suggest
retained graft antitumor reactions following TLI-ATG.82
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Introduction: Follicular lymphoma (FL) is an indolent non-
Hodgkin lymphoma characterized by high response rates
and long response duration(s) to therapy. In the relapsed/
refractory setting (rel/ref), high-dose therapy and autologous
stem cell rescue (HDT-ASCR) and non-myeloablative (NMA)
allogeneic stem cell transplantation (alloSCT) are deﬁnitive
therapies shown to provide long term disease free intervals.
To date, there remains an inherent difﬁculty in deciding the
appropriate consolidative transplant modality in rel/ref FL.
Therefore, we conducted an analysis of clinical features of FL
pts undergoing ﬁrst HDT-ASCR or alloSCT.
Methods: We retrospectively reviewed all pts with rel/ref FL
that proceeded to HDT-ASCR or NMA alloSCT at MSKCC
between 2006 and 2010. Chemosensitive disease was
deﬁned as a partial response (PR) or complete response (CR)
to the last treatment regimen prior to transplant by
computed tomography scans per IWG Criteria. Events were
deﬁned as progression of FL or death from any cause. Event-
free survival (EFS) and overall-survival (OS) were estimated
using Kaplan-Meier method.
Results: We identiﬁed 40 pts with rel/ref FL who had HDT-
ASCR (N¼20) or alloSCT (N¼20). Pts characteristics are out-
lined in the table below: The median follow-up for
survivors is 34 months. The estimated 3-year EFS and OS was60% and 62% with HDT-ASCR and 79% and 85% with alloSCT
respectively (p¼ns). FL pts with remission duration  12
months prior to re-induction therapy proceeding to con-
solidative HDT-ASCR had signiﬁcantly shorter EFS compared
to those pts with previous remission duration > 12 months
(P < 0.05, Figure 1). Furthermore, when HDT-ASCR and
alloSCT pts with a previous remission duration  12 months
prior to re-induction therapy were compared the estimated
3-year EFS was 79% for alloSCT and 36% for HDT-ASCR (P <
0.03). With relatively short follow-up, there was no differ-
ence in OS for these two groups.
Conclusion: The management of rel/ref FL remains a clini-
cally complex topic. In this exploratory analysis we demon-
strated that remission duration of  12 months prior to re-
induction chemotherapy is suggestive of inferior disease
control with HDT-ASCR. Longer follow-up is necessary to
determine the OS impact. Given the relatively unfavorable
pre-transplant characteristics of the alloSCT cohort, FL
appears to be exquisitely sensitive to an allogeneic effect.
Figure 1. EFS HDT-ASCR by Remission Duration to Re-induction.
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